Adopting and implementing an efficacious peer-delivered physical activity program for web platform delivery in survivors of breast cancer: organizational readiness and perspectives.

The Moving forward together (MFT) program is a 3-month, peer-led, physical activity (PA) program for survivors of breast cancer and has shown effectiveness in increasing survivors' moderate-to-vigorous PA. We adapted an existing web-based platform to the MFT program, created webMFT, and partnered with four cancer care organizations to implement webMFT. To understand factors that influence adoption, implementation, and potential for maintenance of webMFT at the organizational level. We used mixed methods to assess organizational readiness and facilitators/barriers for the organizational adoption and implementation of webMFT. In the preimplementation phase, eight representatives completed the organizational readiness for implementing change (ORIC) measure [2 subscales: commitment to change (CC) and efficacy for change (EC), score range = 1-5]. After implementation, four representatives also participated in a semistructured interview. Interviews were coded by two researchers using content analysis. Quantitative and qualitative results were integrated. ORIC scores showed high readiness: CC (mean ± SD; 4.42 ± 0.65) and EC (3.98 ± 0.64). Qualitative categories aligned with quantitative results and included: (i) Strong alignment of mission between webMFT and organizations; (ii) Motivation to adopt webMFT to support their communities; (iii) Lower organizational capacity to recruit participants to receive webMFT than capacity to recruit peer mentors to deliver webMFT; (iv) Resource needs-to scale out and sustain webMFT requires dedicated organizational staff time; and (v) Organizational members found webMFT staff helpful, professional, and communicative, which made partnering a positive experience. Organizational perspectives provided insights into challenges and opportunities for the scalability of evidence-based programs for cancer survivors. The Clinical Trials Registration #: NCT05409664.